Latest News and Press Releases

SAN FRANCISCO and VANCOUVER, British Columbia, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Jade Biosciences, Inc. (“Jade”), (Nasdaq: JBIO), a biotechnology company focused on developing best-in-class...

Jade Biosciences Announces New Data Presentations for JADE101 at the American Society of Nephrology Kidney Week 2025

Jade Biosciences Announces JADE201, a Potentially Best-in-Class Half-Life Extended Afucosylated Anti-BAFF Receptor Monoclonal Antibody

Jade Biosciences Announces $135 Million Private Placement

First Cohort Dosed in Phase 1 Healthy Volunteer Clinical Trial of JADE101

Jade Biosciences to Participate in Upcoming Conferences

Jade Biosciences Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Jade Biosciences to Participate in Two Upcoming Investor Conferences

Jade Biosciences Appoints Brad Dahms as Chief Financial Officer

Jade Biosciences Presents JADE101 Preclinical Data at 62nd European Renal Association Congress Demonstrating Potential for Best-in-Class Profile in IgAN